APO2 ligand: a novel lethal weapon against malignant glioma?
about
Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosisSafety and antitumor activity of recombinant soluble Apo2 ligand.APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis.mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cellsPredominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.Apoptosis in oncology.Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivoDetection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein.Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.Immunochemical characteristics of a novel cell death receptor and a decoy receptor on granulosa cells of porcine ovarian folliclesNanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for GlioblastomaFunctional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-XL and Bcl-2.Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomasIn vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and TemozolomideAntitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells.Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new?Encapsulated stem cells for cancer therapy.Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimerClinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas.Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells.Neural stem cell-based gene therapy for brain tumors.Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatinQuercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells.Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.TRAIL-induced apoptosis in U-1242 MG glioma cells.Cancer gene therapy using a novel secretable trimeric TRAIL.Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells.
P2860
Q31087174-44A2C33E-9C0B-4F39-9540-0F83913F36FAQ33378957-FEF677D2-3BFF-4D19-9E5D-029AE92654D4Q33855449-D8DC5BCB-58B2-47EA-9D61-00F386C397D5Q34090695-D0934FD7-84B9-4BCC-992E-74718AADC6BDQ34097241-530E425E-A043-4C4C-BCF0-B1AFCEAE97C9Q34132999-C70CED69-DB3C-4C89-A375-2FD8BA038CE5Q34220661-C964AB5C-BF00-4D5A-86FA-AD94DD659D0AQ34272896-10106381-A2AD-48B1-A554-ED9BB41C24D5Q34722539-9221272C-FF83-43BA-85D5-FE0099B42B68Q35020357-9C9402CA-4E29-4B0D-A104-6894DA65C660Q35077031-850B1184-5039-429C-A7C2-6C7258C9D63CQ35543789-8709D536-57F8-49EA-9FA5-52AD90D5761BQ35678312-6258668E-21A1-470F-82FB-9996802D3A7FQ36118431-DE6C7E2D-C548-40AE-B5BD-9ED4259D7EECQ36304619-87B64E75-7CE8-4792-AA57-64F1EBD08516Q36470507-DF0AE128-982D-424E-B30F-5FA289A5A6E2Q36648820-F6782E7A-5A60-4589-8D30-F230ED2A391BQ36695971-FD975F0D-35F3-4E8D-AC6F-D45F2A36A4D0Q36786006-CFB1AB99-A602-4E65-9754-9AF87C482604Q37356520-02D25229-7B41-4B10-9DCC-3BD24290230AQ37425788-7C2C2AE2-BD5C-47D2-AFDE-8F653780FFC2Q37761935-74B7AE9E-B4B8-4990-994C-789946BB1A01Q38070361-DBAF2610-3F16-4026-9324-4A2B0F4140D9Q38090923-ED8B6AE6-C1CE-49D8-9401-04D2CA7EF36BQ38673432-DF588B96-52BD-45B1-8D30-CD416F8EF6B1Q38807560-F959FAFD-6A30-4618-A4C1-F789CE808778Q38869957-036FBA19-688C-4992-AB43-EC226D78935BQ38967029-E1330F57-6A6D-4FFD-94A6-5A19865EFBC9Q38981224-CB8858C8-7975-4157-B749-9E90CE848EA4Q39137284-3DD27EDB-6366-4B9D-87B1-B2E9A53797C9Q39162763-3B0BFEB4-F70B-4390-897F-09861D38F699Q39710105-3B24F23F-18BC-490F-AEC0-0DE214F1F0C9Q39923672-005E1962-7604-46A0-833B-06092DD60134Q40002391-119F7BF9-D545-4108-90F8-1BC0FFA0E2E5Q40023794-1D24A705-3427-4E2C-A485-C31D0A22CFDEQ40070572-1021A5B9-22EF-4AA3-AE00-1FF05F187C81Q40319830-F70C2B27-65C6-434D-BD67-0E6E0C207BFBQ40367155-E01566B3-C5B6-4B83-84C4-AB70EA23AAB6Q40494567-9386C6A7-7FA6-4F66-BAE4-C700E408D80CQ40605290-742E724F-A411-4A6E-8ADF-1E7709E2469C
P2860
APO2 ligand: a novel lethal weapon against malignant glioma?
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
APO2 ligand: a novel lethal weapon against malignant glioma?
@ast
APO2 ligand: a novel lethal weapon against malignant glioma?
@en
APO2 ligand: a novel lethal weapon against malignant glioma?
@nl
type
label
APO2 ligand: a novel lethal weapon against malignant glioma?
@ast
APO2 ligand: a novel lethal weapon against malignant glioma?
@en
APO2 ligand: a novel lethal weapon against malignant glioma?
@nl
prefLabel
APO2 ligand: a novel lethal weapon against malignant glioma?
@ast
APO2 ligand: a novel lethal weapon against malignant glioma?
@en
APO2 ligand: a novel lethal weapon against malignant glioma?
@nl
P2093
P1433
P1476
APO2 ligand: a novel lethal weapon against malignant glioma?
@en
P2093
P356
10.1016/S0014-5793(98)00409-8
P407
P577
1998-05-01T00:00:00Z